HCPCS Level II code M0238 describes a second-dose intravenous infusion of tocilizumab-anoh for hospitalized adult patients with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO); service type is drug infusion with post-administration monitoring, and typical site of service is an inpatient hospital setting during the same hospitalization where respiratory support and corticosteroid therapy are provided.

For related coverage guidance, see recent payer policy updates: Clinical Review Criteria — Lymphedema Therapy and Training (Complete Decongestive Therapy; LVA), Therapy Services — Electric Stimulation for Pain, Swelling and Function in a Clinic Setting, Site of Care: Outpatient Hospital Setting for Physical and Occupational Therapy.